Ablation therapy in differentiated thyroid cancer with recombinant TSH.
Recruiting
- Conditions
- gedifferentieerd schildkliercarcinoomdifferentiated thyroid cancerablation therapyablatie therapierecombinant TSH thyroid hormone withdrawalschildklierhormoon onttrekkingI-131 therapie
- Registration Number
- NL-OMON23578
- Lead Sponsor
- Prof.dr. T.P. Links, endocrinologist
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 144
Inclusion Criteria
1. Low and high risk patients (according American Joint Committee on Cancer, AJCC 6) with recently diagnosed histological proven DTC, who have to be treated with ablation therapy. TNM stages T1>1cm, T2, T3, N0, N1, M0 are to be included;
2. Aged 18 years or older;
Exclusion Criteria
1. Stage T4;
2. Stage M1 when known before ablation;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Successful ablation defined as: rhTSH Tg<1ng/ml, negative rhTSH dx WBS, negative US and negative Tg antibodies.
- Secondary Outcome Measures
Name Time Method